- The two studies presented at ASH highlight new data on genomic and immune biomarkers, as well as biological pathways of the aggressive cancer diffuse large B-cell lymphoma (DLBCL), the most common form of B-cell cancer.
- CGI’s proprietary next generation sequencing (NGS) panel, FOCUS::Lymphoma™, was utilized in the search for genomic signatures to use in the selection of DLBCL patients to benefit from novel therapies.
RUTHERFORD, N.J., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in enabling precision medicine for oncology through the use of molecular markers and information, announced today that it will present two podium presentations on diffuse large B-cell lymphoma (DLBCL) in collaboration with Keck School of Medicine of University of Southern California (USC) and Weill Cornell Medical College.
The first presentation, “PD-L1 Expression Identifies High Risk Diffuse Large B-Cell Lymphoma and is Associated with Several Genomic Markers,” is scheduled to take place on Saturday, December 3, 12:30pm. The study with Keck School of Medicine of USC utilized CGI’s proprietary, comprehensive and clinically actionable next generation sequencing (NGS) panel, Focus::Lymphoma™, with 220 genes most commonly mutated in B-cell non-Hodgkin Lymphoma (NHL), to explore rational and reliable biomarkers for selecting DLBCL patients to benefit from checkpoint inhibitor therapies. Additionally, the study explored PD-L1 expression and the variable sensitivity, specificity and dynamic range of three anti-PD-L1 antibodies in a cohort of 52 primary DLBCL patients. CGI believes that this work is essential in developing durable and reliable immune biomarkers and companion diagnostics for selecting lymphoma patients most likely to benefit from immune-checkpoint therapy.
The second presentation, “AICDA Introduces Epigenetic Plasticity in Germinal Center-Derived Lymphomas and Accelerates Lymphomagenesis,” is in concert with Weill Cornell Medical College, and will be presented on Monday, December 5th at 4:30pm. Previous work has established inferior outcomes in DLBCL and is associated with higher degrees of intra-tumor and inter-tumor cytosine methylation heterogeneity, although the molecules driving this epigenetic perturbation remain unknown. The trial with Weill Cornell Medical College investigated the contribution of activation-induced cytidine deaminase (AICDA) to cytosine methylation heterogeneity in DLBCLs. CGI believes that understanding these pathways will be critical in developing new breakthrough therapies for DLBCL and in better understanding different patient subsets that will lead to precision care in DLBCL.
To learn more about CGI's offerings for DLBCL, please refer to DLBCL Complete™ - a unique suite of common and proprietary tests integrating the latest diagnostic and prognostic molecular markers to assist in risk stratification of individual DLBCL patients for disease progression, response to treatment, and overall prognosis.
Representatives from CGI will also be exhibiting the wide range of its products and services at the conference at booth 4543.
ABOUT CANCER GENETICS
Cancer Genetics Inc. is a leader in enabling precision medicine in oncology from bench to bedside through the use of oncology biomarkers and molecular testing. CGI is developing a global footprint with locations in the US, India and China. We have established strong clinical research collaborations with major cancer centers such as Memorial Sloan Kettering, The Cleveland Clinic, Mayo Clinic, Keck School of Medicine at USC and the National Cancer Institute.
The Company offers a comprehensive range of laboratory services that provide critical genomic and biomarker information. Its state-of-the-art reference labs are CLIA-certified and CAP-accredited in the US and have licensure from several states including New York State.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Cancer Genetics Inc.’s expectations regarding future financial and/or operating results and potential for our tests and services, and future revenues or growth in this press release constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that anticipated benefits from acquisitions will not be realized, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Cancer Genetics, Inc. Form 10-K for the year ended December 31, 2015 and the Form 10-Q for the Quarter ended September 30, 2016 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics, Inc. disclaims any obligation to update these forward-looking statements.
Contact: Panna Sharma Cancer Genetics, Inc. 201-528-9200 email@example.com